Header

Prostate Cancer Clinical Trials

Category:Adult
Status:Active

Displaying all 24 trials

Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer

We are studying whether men being treated for prostate cancer have the same amount of side effects from either one of two different external radiation treatments: IMRT or PBT. With IMRT, a number o...

Diagnosis: Prostate Cancer

Phase: 3

Protocol Number: 11-497

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

The purpose of this study is to determine the effectiveness of enzalutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone analogue (LHRHA) in m...

Diagnosis: Prostate Cancer, Radiation Oncology

Phase: 3

Protocol Number: 15-038

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to look for markers of how Ra-223 improves the lives of men with prostate cancer. This study makes use of Ra-223 in the standard FDA-approved way, but adds non-standard...

Diagnosis: Prostate Cancer

Phase: 2

Protocol Number: 14-375

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

This research study is studying the use of a targeted therapy called LY SARM, which is an investigational drug from a new class of molecules called Selective Androgen Receptor Modulators (SARMs) as...

Diagnosis: Prostate Cancer

Phase: 2

Protocol Number: 15-120

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.

Diagnosis: Prostate Cancer

Phase: 2

Protocol Number: 15-453

Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy

This research study is studying a combination of drugs called abiraterone acetate and ARN-509 as a possible treatment for new diagnosed Prostate Cancer. The following interventions will be use in t...

Diagnosis: Prostate Cancer

Phase: 2

Protocol Number: 16-223

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

This study is a Phase 1/2 open-label involving 2 groups of patients newly diagnosed with either unfavorable intermediate risk or high risk prostate adenocarcinoma. One group will receive only EBRT ...

Diagnosis: Radiation Oncology, Prostate Cancer

Phase: 1 / 2

Protocol Number: 16-445

Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

This study will evaluate a method to detect tumor cells that are circulating in the blood without getting a biopsy. The investigators already know from other studies that cancer tumors shed a small...

Diagnosis: Prostate Cancer

Phase: N/A

Protocol Number: 08-207

Focal MR-Guided Focused Ultrasound Treatment of Localized Low and Intermediate Risk Prostate Cancer

The hypothesis of this feasibility study is that focal treatment with ExAblate MRgFUS has the potential to be an effective non-invasive treatment for low risk, organ-confined prostate cancer, with ...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 13-184

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

This study consists of two phases: Dose Escalation (Phase 1b) and Dose Expansion (Phase 2) The Dose Escalation phase will evaluate the safety and tolerability of GS-5829 as a single agent and in co...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 15-343

Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer (OSPREY)

This study evaluates the safety and diagnostic performance characteristics of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 16-539

Efficacy and Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)

The purpose of this study is to assess the safety and efficacy of BAY1841788 (ODM-201) in patients with non-metastatic castration-resistant prostate cancer.

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 16-367

Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy

This research study is evaluating the impact and feasibility of a 12-week brisk walking and moderate strength training exercise intervention including a virtual component in men who are initiating ...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 16-515

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving p...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 16-244

Study of a Recombinant Adenovirus to Treat Localized Prostate Cancer

The purpose of this study is to evaluate the safety and effectiveness of AD5-SGE-REIC/Dkk-3 in subjects with localized prostate cancer.

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 16-601

Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC

This research study is studying the safety and tolerability of an investigational combination of drugs, radium-223 plus pembrolizumab as a possible treatment for castration-resistant prostate cance...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 16-498

A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer

This research study is studying a combination of drugs as a possible treatment for castration-resistant prostate cancer. The interventions involved in this study are: - Docetaxel (a type of chemoth...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 16-485

Olaparib With or Without Cediranib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body. ...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 17-710

ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with m...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 17-120

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of

This Phase III, multicenter, randomized, open-label study will evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) in combination with enzalutami...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 17-182

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 17-303

Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)

This randomized controlled trial aims to evaluate the impact of pre-test video education and post-test genetic counseling as compared to in-person pre-test genetic counseling in males with advanced...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 17-409

Prostvac in Patients With Biochemically Recurrent Prostate Cancer

Background: Some people who have been treated for prostate cancer still have high prostate-specific antigen (PSA) levels. This may indicate cancer. These people have non-metastatic castration sensi...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 17-223

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer

The study aims to evaluate the combination of GSK525762 with other agents that have been shown to be effective in the treatment of CRPC or metastatic CRPC, including approved agents (e.g., abirater...

Diagnosis: Prostate Cancer

Phase:

Protocol Number: 17-369

'